JP2001509512A5 - - Google Patents

Download PDF

Info

Publication number
JP2001509512A5
JP2001509512A5 JP2000502063A JP2000502063A JP2001509512A5 JP 2001509512 A5 JP2001509512 A5 JP 2001509512A5 JP 2000502063 A JP2000502063 A JP 2000502063A JP 2000502063 A JP2000502063 A JP 2000502063A JP 2001509512 A5 JP2001509512 A5 JP 2001509512A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
nucleotide
independently represent
components
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000502063A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001509512A (ja
JP4950380B2 (ja
Filing date
Publication date
Priority claimed from SE9702680A external-priority patent/SE9702680D0/xx
Application filed filed Critical
Publication of JP2001509512A publication Critical patent/JP2001509512A/ja
Publication of JP2001509512A5 publication Critical patent/JP2001509512A5/ja
Application granted granted Critical
Publication of JP4950380B2 publication Critical patent/JP4950380B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2000502063A 1997-07-11 1998-06-29 新規な製剤 Expired - Lifetime JP4950380B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9702680A SE9702680D0 (sv) 1997-07-11 1997-07-11 New formulation
SE9702680-1 1997-07-11
PCT/SE1998/001287 WO1999002542A1 (en) 1997-07-11 1998-06-29 New formulation

Publications (3)

Publication Number Publication Date
JP2001509512A JP2001509512A (ja) 2001-07-24
JP2001509512A5 true JP2001509512A5 (enExample) 2006-01-05
JP4950380B2 JP4950380B2 (ja) 2012-06-13

Family

ID=20407718

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000502063A Expired - Lifetime JP4950380B2 (ja) 1997-07-11 1998-06-29 新規な製剤

Country Status (35)

Country Link
US (1) US6130208A (enExample)
EP (1) EP1000079B1 (enExample)
JP (1) JP4950380B2 (enExample)
KR (1) KR100786654B1 (enExample)
CN (2) CN1864696A (enExample)
AR (1) AR013157A1 (enExample)
AT (1) ATE340801T1 (enExample)
AU (1) AU8362598A (enExample)
BR (1) BR9810703A (enExample)
CA (1) CA2295628C (enExample)
CY (1) CY1105805T1 (enExample)
CZ (1) CZ298110B6 (enExample)
DE (1) DE69836023T2 (enExample)
DK (1) DK1000079T3 (enExample)
EE (1) EE04119B1 (enExample)
ES (1) ES2273425T3 (enExample)
HU (1) HU226489B1 (enExample)
ID (1) ID24716A (enExample)
IL (2) IL133868A0 (enExample)
IS (1) IS2439B (enExample)
MY (1) MY116421A (enExample)
NO (1) NO329918B1 (enExample)
NZ (1) NZ502073A (enExample)
PL (1) PL192768B1 (enExample)
PT (1) PT1000079E (enExample)
RU (1) RU2216330C2 (enExample)
SA (1) SA98190328B1 (enExample)
SE (1) SE9702680D0 (enExample)
SI (1) SI1000079T1 (enExample)
SK (1) SK285766B6 (enExample)
TR (1) TR200000006T2 (enExample)
TW (1) TW585764B (enExample)
UA (1) UA65576C2 (enExample)
WO (1) WO1999002542A1 (enExample)
ZA (1) ZA985669B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879567B2 (en) * 2004-10-05 2011-02-01 Asahi Kasei Pharma Corporation Method for stabilizing coenzyme and composition therefor
US20120141468A1 (en) * 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
JP5597202B2 (ja) 2009-08-28 2014-10-01 第一三共株式会社 3−(ビアリールオキシ)プロピオン酸誘導体
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2011060066A2 (en) 2009-11-11 2011-05-19 The Medicines Company Methods of treating or preventing stent thrombosis
WO2013025697A1 (en) 2011-08-17 2013-02-21 Samuel Shiber Adaptive rotary catheter for opening obstructed bodily vessels
FI2648701T3 (fi) * 2010-12-10 2023-06-12 Sigmapharm Laboratories Llc Hyvin stabiileja adefovirdipivoksiilin koostumuksia
RU2599490C2 (ru) 2011-02-09 2016-10-10 Зе Медисинс Компани Способы лечения легочной гипертензии
EA034550B1 (ru) 2013-03-09 2020-02-19 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способы лечения, снижения частоты и/или профилактики ишемических событий
CN103772461A (zh) * 2014-01-06 2014-05-07 南京正科制药有限公司 一种坎格雷洛晶型ⅰ
MX391152B (es) 2015-01-14 2025-03-21 Chiesi Farm Spa Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.
WO2018234565A1 (en) 2017-06-23 2018-12-27 Chiesi Farmaceutici S.P.A. Method of preventing of systemic-to-pulmonary-artery shunt thrombosis
TWI857957B (zh) 2018-06-19 2024-10-11 德商Ucb製藥有限公司 吡啶基及吡基-(氮)吲哚磺醯胺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5637967B2 (enExample) * 1973-05-17 1981-09-03
JPS5874966A (ja) * 1981-10-28 1983-05-06 Mikuni Jukogyo Kk 高圧往復動機の軸封装置
JPS5874696A (ja) * 1981-10-30 1983-05-06 株式会社 ヤトロン アデノシン三リン酸の安定化方法
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
US5563122A (en) * 1991-12-09 1996-10-08 Asahi Kasei Kogyo Kabushiki Kaisha Stabilized parathyroid hormone composition
AU679721B2 (en) * 1993-02-10 1997-07-10 Astrazeneca Ab N-alkyl-2-substituted ATP analogues
PE36795A1 (es) * 1993-12-14 1995-11-06 Lilly Co Eli Complejo de inclusion en solucion acuosa de compuestos de benzotiofeno con ciclodextrinas solubles en agua, formulaciones farmaceuticas y procedimiento de obtencion
DE4405426A1 (de) * 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
AU707734B2 (en) * 1995-06-07 1999-07-15 Regents Of The University Of California, The Stabilization of polynucleotide complexes
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
SE9604795D0 (sv) * 1996-12-20 1996-12-20 Astra Pharma Prod New pharmaceutical formulation

Similar Documents

Publication Publication Date Title
JP2001509512A5 (enExample)
FI104176B (fi) Menetelmä nukleosidien uusien antiviraalisten forfolipidijohdannaisten valmistamiseksi
JP7124024B2 (ja) Rnaウイルス治療に対する2’-置換-n6-置換プリンヌクレオチド
CN104640444B (zh) 双肝脏靶向氨基磷酸酯和氨基膦酸酯前药
JP3083156B2 (ja) N−アルキル−2−置換atp類似体
CN100434079C (zh) 吡嗪核苷酸/吡嗪核苷类似物及其医药用途
EP1012154B1 (en) Salts of di(uridine 5'-tetraphosphate), method for preparation and uses thereof
EP0785208B1 (en) Phosphonate nucleotide compounds
JP2018517709A (ja) 選択的な無溶媒リン酸化
HUT73659A (en) New antiviral nucleoside derivatives
JP6909157B2 (ja) エンドキャップされた核酸分子
WO2001060834A1 (en) Novel pyrazine derivatives or salts thereof, pharmaceutical compositions containing the derivatives or the salts and intermediates for the preparation of both
JP2001522369A (ja) 抗ウイルスピリミジンヌクレオシド類似体
JPH05247070A (ja) プリンとピリミジンの新規な不飽和非環式ホスホネート誘導体類
Česnek et al. Synthesis of 9-phosphonoalkyl and 9-phosphonoalkoxyalkyl purines: Evaluation of their ability to act as inhibitors of Plasmodium falciparum, Plasmodium vivax and human hypoxanthine–guanine–(xanthine) phosphoribosyltransferases
CA2890676A1 (en) Phosphonucleosides useful in the treatment of viral disorders
HU217772B (hu) 3'-Helyettesített nukleozidszármazékok, eljárás ezek előállítására és ezeket tartalmazó gyógyszerkészítmények
US7091334B2 (en) Method for large-scale production of di(uridine 5′)-tetraphosphate and salts thereof
RU2000103216A (ru) Новая композиция
JP2001509512A (ja) 新規な製剤
HU204843B (en) Process for producing 2'-halogen-methylidene adenosine derivatives and pharmaceutical compositions comprising same
EP4516798A1 (en) Nucleoside drug for treating or preventing coronavirus infection, and use thereof
JPS6411637B2 (enExample)
US6548658B2 (en) Di-(uridine 5′)-tetraphosphate and salts thereof
WO1989005817A1 (en) Antitumor 6-sulfenamide, 6-sulfinamide and 6-sulfonamide purines, purine nucleosides, purine nucleotides and related compounds